Lisa Blackwell
Senior Statistical Programmer
- Vascular Overviews Group/Renal Studies Group
Lisa is a Senior Statistical Programmer at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU).
She completed her degree in Applied Statistics at the University of Plymouth, and is now the statistical programming lead for the ATT (Anti-Thrombotic Trialists’ Collaboration), CTT (Cholesterol Treatment Trialists’ Collaboration) and STT (Stroke Thrombolysis Trialists’ Collaboration) projects within the CTSU’s Vascular Overviews Group.
Her research interests focus on cardiovascular disease, large-scale individual participant meta-analyses of randomised studies and methods for harmonisation of large-scale heterogeneous IPDs.
She is a member of the board of examiners for the Oxford Population Health MSc in Clinical Trials and an assessor for MSc in Global Health Science.
Recent publications
ssessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists’ (CTT) Collaboration ., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Journal article
Cholesterol Treatment Trialists' Collaboration ., (2022), Clin Trials, 19, 593 - 604
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Journal article
Cholesterol Treatment Trialists' Collaboration ., (2022), Lancet, 400, 832 - 845
Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy
Journal article
BAIGENT C. et al, (2022), The Lancet
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' Collaboration ., (2019), Lancet, 393, 407 - 415
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
Journal article
3C Study Collaborative Group ., (2018), Am J Transplant, 18, 1424 - 1434
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
Journal article
Hacke W. et al, (2018), Int J Stroke, 13, 175 - 189
Interpretation of the evidence for the efficacy and safety of statin therapy.
Journal article
Collins R. et al, (2016), Lancet, 388, 2532 - 2561
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration . et al, (2016), Lancet Diabetes Endocrinol, 4, 829 - 839